Dossier assessment
Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult men with metastatic hormone-sensitive prostate cancer
Result of dossier assessment:
Indication of major added benefit
Additional information
Federal Joint Committee (G-BA)
2023-09-21 A G-BA decision was published.
Project details
- Project no.
- A23-21
- Commission
- Commission awarded on 27.03.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Darolutamide (prostate cancer) - Addendum to Commission A23-21
Status: Commission completed
-
Dossier assessment
Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed